Skip to main content
2025 AABB Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Event Icons
Assessor Sessions
Assessor Sessions
Committee Meetings
Committee Meetings
Foundation Events
Foundation Events
Networking Events
Networking Events
Oral Abstracts
Oral Abstracts
CABP Eligible
CABP Eligible
Video Recording

THOR

AM25-ST-25-L - AABB/THOR Joint Session: Some New Looks at Old Dogma, New Studies, and New Blood Products

Saturday, October 25, 2025
8:15 AM - 12:15 PM  PT
Room: SDCC 20A
CE: 3.0 CME (AMA Physician Credit) / 3.0 CE (Non-Physician Credit)

    Program Chair(s)

  • Audra L. Taylor, MS, SBB(ASCP)

    Vice President, Blood and Tissue Operations
    South Texas Blood & Tissue
    San Antonio, Texas

    Disclosure information not submitted.

  • Bethany Brown

    Sr. Director, Transfusion Innovation & Product Development
    American Red Cross
    Rockville, Maryland

    Disclosure(s): Cerus Corp.: Grant/Research Support (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing); Hemanext: Grant/Research Support (Ongoing); Terumo BCT: Grant/Research Support (Terminated, March 31, 2025)

    Handouts

    • Speaker(s)

  • Evan M. Bloch, MBChB, MS

    Professor of Pathology
    Johns Hopkins University School of Medicine
    Baltimore, Maryland

    Disclosure(s): Abbott: Honoraria (Ongoing); Grifols Diagnostic Solutions: Honoraria (Ongoing)

    Handouts

  • Claudia Cohn, MD, PhD (she/her/hers)

    Professor of Laboratory Medicine and Pathology, Director, Blood Bank Laboratory
    University of Minnesota
    Minneapolis, Minnesota

    Disclosure(s): AABB: Consultant/Advisory Board (Ongoing); Cellphire THerapeutics Inc.: Consultant/Advisory Board (Ongoing); Fresenius Kabi: Consultant/Advisory Board (Ongoing); ICCBBA: Board of DIrectors (Ongoing)

    Handouts

  • Martin H. Ellis, MD (he/him/his)

    Director, Blood Bank
    Meir Medical Center
    Kfar Saba, HaMerkaz

    Disclosure(s): No financial relationships to disclose

    Handouts
  • RM

    Ryan A. Metcalf, MD

    Section Chief, Transfusion Medicine
    University of Utah Health
    Salt Lake City, Utah

    Disclosure(s): Haemonetics: Grant/Research Support (Terminated, May 31, 2025); Hemosonics: Grant/Research Support (Terminated, May 31, 2025); Octapharma: Grant/Research Support (Terminated, May 31, 2025); werfen: Grant/Research Support (Terminated, May 31, 2025)

    Handouts

  • Jay S. Raval, MD

    Professor, Department. of Pathology and Laboratory Medicine
    University of Vermont Medical Center
    Burlington, Vermont

    Disclosure(s): Medtronics: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing); Sanofi: Consultant/Advisory Board (Ongoing), Honoraria (Ongoing), Speaker's Bureau (Ongoing); Terumo BCT: Consultant/Advisory Board (Ongoing)

    Handouts

  • Susan M. Shea, MSME, PhD (she/her/hers)

    Assistant Professor
    Trauma and Transfusion Medicine Research Center, Department of Surgery, University of Pittsburgh
    Pittsburgh, Pennsylvania

    Disclosure(s): No financial relationships to disclose

    Handouts

  • Nicole D. Zantek, MD, PhD

    Professor
    Department of Laboratory Medicine and Pathology, University of Minnesota
    Minneapolis, Minnesota

    Disclosure(s): American Society for Apheresis (ASFA): Board Member and Secretary (Ongoing); Boston Scientific: Spouse - stocks, former employee (Ongoing); ENDO International PLC: Spouse - stocks (Ongoing); External Quality Assurance in Thrombosis and Hemostasis (EQATH): Board Member and Secretary/Treasurer (Ongoing); North American Specialized Coagulation Laboratory Association (NASCOLA): Board Member and Vice President (Ongoing)

  • Bethany Weathersby, MEd

    Executive Director
    The Allo Hope Foundation
    Tuscaloosa, Alabama

    Disclosure(s): Billion to One Unity: My institution (AHF) has received educational sponsorships from J&J (Ongoing); Johnson & Johnson: My institution (AHF) has received educational sponsorships from J&J (Ongoing)

    Handouts
  • AC

    Andrew Cap, MD, PhD

    US Army Institute of Surgical Research, Texas

    Disclosure(s): No relevant disclosure to display

    Handouts
This joint session organized by the Trauma, Hemostasis and Oxygenation Research (THOR) Network and the Association for the Advancement of Blood and Biotherapies (AABB), will look both backwards and forwards in time to update the audience on the best practices in providing blood products to patients with life threatening hemorrhage. Some long-held beliefs about hemolysis, platelet production methods, and transfusion futility will be challenged, and an update from the Emergency transfusion in females with childbearing potential consensus conference will be provided, along discussions of cold platelets, liquid plasma, and more.

8:15 – 9:15 Blood Management aspects of Hemostatic Resuscitation
• Liquid plasma as a substitute for whole blood –John Holcomb
• Improving LTOWB availability by reducing inappropriate Group O RBC use – Ryan Metcalf
• Plasma exchange for trauma induced coagulopathy - Jay Raval
• Panel Discussion
09:15 – 9:30 Break
9:30 – 10:30 Changing Practice with LTOWB
• Review of the recommendations from the Emergency transfusion in females with childbearing potential consensus conference – Molly Sherwood
• It’s on! The use of low titer group O whole blood in non-trauma patients – Martin Ellis
• Why are some hospitals not implementing LTOWB? – Evan Bloch
• Panel Discussion
10:30 – 10:45 Break
10:45 – 12:15 Blood Management aspects of Hemostatic Resuscitation (1045-1215)
• CHIPS study update – Nicole Zantek
• Platelet manufacturing methods and platelet quality – Susan Shea
• FDA Guidance and what it means for you – Claudia Cohn
• Panel Discussion

Learning Objectives:

  • Analyze the outcomes of the CHiPS study.
  • Update on the recommendations of a consensus conference on the optimum strategies for resuscitating injured females of childbearing. potential.
  • Learn about the role of plasma exchange in treating trauma induced coagulopathy.